Effects of Glucagon-like Peptide-1 Receptor Agonists and Sodium-glucose Cotransporter 2 Inhibitors on Cardiorenal and Metabolic Outcomes in People Without Diabetes

被引：8
|
作者：
Papazafiropoulou, Athanasia K. [1 ,2 ]
Melidonis, Andreas [3 ]
Antonopoulos, Stavros [1 ,2 ]
机构：
[1] Tzaneio Gen Hosp Piraeus, Dept Internal Med 1, 1 Zanni & Afentouli St, Piraeus 18536, Greece
[2] Tzaneio Gen Hosp Piraeus, Diabet Ctr, 1 Zanni & Afentouli St, Piraeus 18536, Greece
[3] Etropolitan Hosp, Diabet & Cardiometab Ctr, Piraeus, Greece
来源：
CURRENT PHARMACEUTICAL DESIGN | 2021年 / 27卷 / 08期
关键词：
Non-diabetic; SGLT2; inhibitors; GLP-1 receptor agonists; empagliflozin; dapagliflozin; canagliflozin; liraglutide; dulaglutide; exenatide; semaglutide; ONCE-WEEKLY SEMAGLUTIDE; DOUBLE-BLIND; CARDIOVASCULAR OUTCOMES; HEART-FAILURE; BODY-WEIGHT; EXENATIDE TREATMENT; NA+/H+ EXCHANGER; GLYCEMIC CONTROL; SGLT2; INHIBITOR; KIDNEY-DISEASE;
D O I：
10.2174/1381612826666200909142126
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
During the last decade, the results of large-scale, randomized, clinical trials on newer antidiabetic agents, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium glucose cotransporter type 2 (SGLT2) inhibitor, have been published showing promising findings on cardiovascular and renal outcomes. Besides improving glycemic control, GLP-1 receptor agonists have been shown to modify cardiovascular risk factors, such as insulin resistance, body weight, blood pressure (BP), and lipid profile. Additionally, SGLT2 inhibitors except for glycemic control have been shown to induce weight loss and decrease BP. However, there are limited data regarding their effect on patients without diabetes. Therefore, the aim of the present review is to summarize the existing literature data regarding the effects of newer antidiabetic therapies on patients without diabetes.
引用
收藏
页码：1035 / 1042
页数：8
相关论文
共 50 条
  • [31] Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease
    Hofer, Felix
    Kazem, Niema
    Schweitzer, Ronny
    Hammer, Andreas
    Jakse, Friedrich
    Koller, Lorenz
    Hengstenberg, Christian
    Sulzgruber, Patrick
    Niessner, Alexander
    CARDIOVASCULAR DRUGS AND THERAPY, 2021, 35 (06) : 1161 - 1170
  • [32] Comparative effectiveness of insulin glargine, glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in veterans with type 2 diabetes
    Shen, Jincheng
    Sarwal, Amara
    Singh, Ravinder
    Hartsell, Sydney E.
    Wei, Guo
    Nevers, Mckenna
    Christensen, Jesse C.
    Takyi, Augustine
    Katkam, Niharika
    Derington, Catherine G.
    Deshmukh, Vikrant G.
    Boucher, Robert E.
    Drakos, Stavros G.
    Greene, Tom
    Beddhu, Srinivasan
    DIABETES OBESITY & METABOLISM, 2025, 27 (04): : 2120 - 2130
  • [33] Sodium-Glucose Cotransporter-2 Inhibitors versus Glucagon-Like Peptide 1 Receptor Agonists Effects on Kidney and Clinical Outcomes in Veterans with Type 2 Diabetes
    Morello, Candis M.
    Awdishu, Linda
    Lam, Stepfanie
    Heman, Amy
    Bounthavong, Mark
    KIDNEY360, 2024, 5 (11): : 1633 - 1643
  • [34] Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists A One-Two Punch?
    Harrington, Josephine
    McGuire, Darren K.
    Inzucchi, Silvio E.
    JACC-HEART FAILURE, 2024, 12 (11) : 1827 - 1829
  • [35] Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes
    Foresta, Andreana
    Ojeda-Fernandez, Luisa
    Macaluso, Giulia
    Roncaglioni, Maria Carla
    Tettamanti, Mauro
    Fortino, Ida
    Leoni, Olivia
    Genovese, Stefano
    Baviera, Marta
    CLINICAL THERAPEUTICS, 2023, 45 (04) : e115 - e126
  • [36] Glucagon-Like Peptide-1 Receptor Agonists and Sodium Glucose Cotransporter-2 Inhibitors and Cardiorespiratory Fitness Interaction
    Ni, David
    Kokkinos, Peter
    Nylen, Eric S.
    MILITARY MEDICINE, 2024, 189 (11-12) : 2369 - 2373
  • [37] THE ADVISORY BOARD RESOLUTION ON THE USE OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS AND GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS IN TYPE 2 DIABETES
    Antsiferov, Mikhail B.
    Galstyan, Gagik R.
    Demidova, Tatiana Yu.
    Zilov, Alexey, V
    Markova, Tatiana N.
    Mkrtumyan, Ashot M.
    Petunina, Nina A.
    Khalimov, Iurii S.
    Shamkhalova, Minara S.
    Shestakova, Marina, V
    DIABETES MELLITUS, 2023, 26 (02): : 211 - 214
  • [38] Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and the Prevention of Cirrhosis Among Patients With Type 2 Diabetes
    Pradhan, Richeek
    Yin, Hui
    Lu, Sally
    Sebastiani, Giada
    Yu, Oriana
    Suissa, Samy
    Azoulay, Laurent
    DIABETES CARE, 2025, 48 (03)
  • [39] Effects of sodium-glucose contrasporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on vascular function and liver steatosis in diabetes
    Ikonomidis, I.
    Michalopoulou, E.
    Pavlidis, G.
    Prentza, V.
    Katogiannis, K.
    Kostelli, G.
    Vythoulkas, D.
    Kountouri, A.
    Korakas, E.
    Pliouta, L.
    Thymis, J.
    Lambadiari, V.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [40] Evidence-based comparison of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors
    Watada, Hirotaka
    JOURNAL OF DIABETES INVESTIGATION, 2020, 11 (01) : 17 - 19
12345